<DOC>
	<DOCNO>NCT00668395</DOCNO>
	<brief_summary>1 . To see liver break efavirenz enzyme call CYP2B6 . It suggest Efavirenz take repeatedly may increase amount CYP2B6 liver thus speed liver 's ability get rid efavirenz body . This may render efavirenz medication ineffective . 2 . To see efavirenz interact drug take time . 3 . To see genetic difference change way liver break efavirenz interaction co-administered drug .</brief_summary>
	<brief_title>Effects CYP2B6 Genetic Polymorphisms Efavirenz Pharmacokinetics</brief_title>
	<detailed_description>The human hepatic cytochrome P450 2B6 ( CYP2B6 ) key enzyme metabolism grow list clinically important drug , environmental chemical ( e.g . toxicant carcinogen ) endogenous substance . The expression activity enzyme varies widely among individual , probably due genetic polymorphism CYP2B6 gene drug interaction . This variability , turn , likely contributes variable response drug primarily metabolize CYP2B6 . In deed , several drug substrate CYP2B6 exhibit large pharmacokinetic difference among individual use associate unpredictable drug interaction . Therefore , identify mechanism factor might influence CYP2B6 activity important safe effective use substrate . An important characteristic several clinically important CYP2B6 substrate drug include efavirenz , nevirapine , cyclophosphamide , artemisinin ifosfamide ability enhance clearance upon repeat dosing , process know autoinduction metabolism . Drugs autoinduce metabolism also exhibit multiple interaction drug metabolize enzyme CYP2B6 ( e.g . CYP3A , CYP2C9 CYP2C19 ) , drug transporter ( e.g . p-glycoprotein ) . As medication use combination drug , potential alter pharmacokinetics co-administered drug high . We hypothesize CYP2B6 genetic variant influence constitutive CYP2B6 expression activity contribute interindividual variability steady-state exposure autoinducer drug drug interaction ensue . We determine impact CYP2B6 genetic variant , typically CYP2B6*6 allele , time-course extent autoinduction metabolism consequences differential autoinduction drug interaction , use efavirenz ( know CYP2B6 substrate autoinducer ) model drug . Thus , single ( 600 mg oral dose ) steady-state ( 600 mg/day ) pharmacokinetics efavirenz assess healthy subject genotyped CYP2B6*6 allele . Trough concentration efavirenz metabolite collect course efavirenz treatment . Efavirenz exposure compare genotype autoinduction . An autoinduction pharmacokinetic model develop characterize dynamic time course autoinduction different genotype . The potential impact difference efavirenz exposure drug interaction determine measure vivo activity select CYP enzyme , use isoform specific substrate probe [ omeprazole ( CYP2C19 ) , tolbutamide ( CYP2C9 ) , caffeine ( CYP1A2 ) midazolam ( CYP3A ) ] single multiple ( steady-state ) dose efavirenz .</detailed_description>
	<mesh_term>Efavirenz</mesh_term>
	<criteria>1 . Male female subject 18 49 year old . 2 . HIV negative . All potential subject HIV test screen visit . 3 . Healthy individual without significant medical condition . 4 . Adherence study dietary restriction . 5 . Nonsmoker individual willing refrain smoking use tobacco marijuana l one month prior completion study . The entire study last 30 day . 6 . Ability commit time request study . 1 . History current HIV infection . 2 . Life style place high risk contract HIV ( e.g . drug abuse , excessive alcohol drinking , multiple sexual partner ) . 3 . Does consent HIV test . 4 . Underweight ( weigh less 52 kg 114 lb ) overweight ( body mass index ( BMI ) great 32 ) . 5 . History current alcohol drug abuse ( 3 alcoholic drink per day regular basis ) . 6 . History intolerance allergic reaction ( e.g . rash ) efavirenz , midazolam , tolbutamide , caffeine , omeprazole . 7 . History current significant health condition heart , liver , kidney . 8 . History current psychiatric illness depression , anxiety , nervousness . 9 . History current gastrointestinal disorder persistent diarrhea malabsorption would interfere absorption orally administer drug . 10 . Individuals serious infection within last month . 11 . Donation blood within past two month . 12 . Blood hemoglobin le 12.5 mg/dl . 13 . Individuals regularly take prescription , overthecounter , herbal dietary supplement , alternative medication , hormonal agent ( i.e . oral contraceptive , interauterine device hormone ) . 14 . Females positive pregnancy test . 15 . Breastfeeding . 16 . Females childbearing potential unable unwilling either practice abstinence use two nonhormonal form birth control ( e.g . condom , contraceptive foam ) study completion , take total 30 day . 17 . Participation research study use investigational drug last two month . 18 . An employee student supervision investigator study . 19 . Individuals state good understanding study include risk requirement ; unable follow rule study . 20 . Individuals gene type ( DNA ) match one available genetic slot category .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>49 Years</maximum_age>
	<verification_date>September 2014</verification_date>
	<keyword>CYP2B6</keyword>
	<keyword>Efavirenz</keyword>
	<keyword>Pharmacokinetics</keyword>
	<keyword>Pharmacogenetics</keyword>
	<keyword>Drug-Interactions</keyword>
</DOC>